GlassScriptPhysician profile
Rodney B Young
NPI 1942235080
$2,239.71
in general payments reported to CMS, 2019-2025
22 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $33.93 · 2021: $406 · 2022: $301 · 2023: $499 · 2024: $490 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $551.74 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $345.86 | 2020-2025 | |
| Astellas Pharma US INC | $195.28 | 2019-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $157.50 | 2021 | |
| Lilly USA, LLC | $132.76 | 2019-2025 | Kisunla, Zepbound |
| Janssen Pharmaceuticals, INC | $103.23 | 2019-2024 | Xarelto |
| Lundbeck LLC | $98.08 | 2021 | |
| Merck Sharp & Dohme LLC | $91.61 | 2020-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Astrazeneca Pharmaceuticals LP | $82.15 | 2023-2025 | Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $73.39 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $72.16 | 2023 | Austedo Xr, Ajovy |
| Dexcom, INC. | $61.01 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $46.20 | 2022-2025 | Bexsero, Rotarix, Pediarix |
| Allergan, INC. | $45.08 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $32.20 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.75 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $27.24 | 2024 | Glassia |
| Vapotherm INC | $24.94 | 2022 | |
| Sanofi Pasteur INC. | $23.15 | 2019 | |
| Henry Schein, INC. | $18.76 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.39 | 2024 | Keveyis |
| Circassia INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.